Published in Pediatrics on June 01, 1999
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest (2000) 5.52
Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol (2008) 2.63
Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin (2010) 1.98
Cherubism: best clinical practice. Orphanet J Rare Dis (2012) 1.42
A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecol Oncol (2007) 1.31
Heterogeneous vascular dependence of tumor cell populations. Am J Pathol (2001) 1.31
Serial magnetic resonance spectroscopy reveals a direct metabolic effect of cediranib in glioblastoma. Cancer Res (2011) 1.13
Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives. J Cancer Res Clin Oncol (2004) 1.12
The diagnosis and management of giant cell lesions of the jaws. Ann Maxillofac Surg (2012) 1.06
Modern interpretation of giant cell tumor of bone: predominantly osteoclastogenic stromal tumor. Clin Orthop Surg (2012) 1.00
Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-alpha. Neoplasia (2001) 0.90
Judah Folkman, a pioneer in the study of angiogenesis. Angiogenesis (2008) 0.90
Giant cell tumour of bone: new treatments in development. Clin Transl Oncol (2015) 0.87
Clinico-pathologic conference AAOMP/IAOP 2008: case 3. Head Neck Pathol (2008) 0.85
Treatment of cherubism with salmon calcitonin: a case report. Eur J Dent (2011) 0.83
Central giant cell granuloma of the jaws: clinical and radiological evaluation of 22 cases. Skeletal Radiol (2009) 0.82
Retrospective analysis of patients with rare-site and metastatic giant cell tumor. Chin J Cancer Res (2013) 0.81
Interferon and giant cell tumors. Pediatrics (1999) 0.77
'Salvage Treatment' of Aggressive Giant Cell Tumor of Bones with Denosumab. Cureus (2015) 0.76
ECOG phase II trial of graded-dose peginterferon α-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602). Clin Cancer Res (2013) 0.76
Seven-year survival after intralesional resection and adjuvant radiotherapy for a giant-cell tumour of the sixth cervical vertebra. Can J Surg (2009) 0.75
Unusual Presentation of Giant Cell Tumor in Skeletally Immature Patient in Diaphysis of Ulna. J Orthop Case Reports (2016) 0.75
Giant cell tumor of temporal bone: A case report. Med J Armed Forces India (2012) 0.75
Injection of steroids intralesional in central giant cell granuloma cases (giant cell tumor): Is it free of systemic complications or not? A case report. Int J Surg Case Rep (2015) 0.75
Central giant cell granuloma of posterior maxilla: first expression of primary hyperparathyroidism. Case Rep Endocrinol (2015) 0.75
Treatment of giant cell granuloma with intralesional corticosteroid injections: a case report. J Istanb Univ Fac Dent (2015) 0.75
Central giant cell granuloma: treatment with calcitonin, triamcinolone acetonide, and a cystic finding 3 years and 6 months after the primary treatment. Oral Maxillofac Surg (2012) 0.75
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 23.99
Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med (1991) 19.46
Angiogenic factors. Science (1987) 15.22
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 13.94
Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell (1994) 13.76
What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst (1990) 13.41
Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg (1982) 12.85
Role of cell shape in growth control. Nature (1978) 12.46
Phylogenetic perspectives in innate immunity. Science (1999) 9.42
Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst (1992) 8.69
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (1997) 7.66
Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell (1997) 7.47
Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med (1995) 7.37
Isolation of a tumor factor responsible for angiogenesis. J Exp Med (1971) 7.12
Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol (1993) 6.55
Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A (1994) 6.48
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res (2000) 6.42
Human vascular endothelial cells in culture. Growth and DNA synthesis. J Cell Biol (1974) 5.95
Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol (1994) 5.76
Long-term culture of capillary endothelial cells. Proc Natl Acad Sci U S A (1979) 5.70
Tumor angiogenesis. Adv Cancer Res (1985) 5.66
Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res (1977) 5.19
Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature (1990) 5.15
Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell (1996) 5.10
Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science (1999) 4.91
Mechanochemical switching between growth and differentiation during fibroblast growth factor-stimulated angiogenesis in vitro: role of extracellular matrix. J Cell Biol (1989) 4.85
Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci U S A (1987) 4.83
Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med (1992) 4.76
Angiogenesis in vitro. Nature (1980) 4.46
Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg (1972) 4.37
Tumor dormancy in vivo by prevention of neovascularization. J Exp Med (1972) 4.34
Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. Science (1984) 4.27
Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst (1974) 4.05
Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol (1994) 3.76
Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med (1996) 3.64
Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst (1995) 3.53
Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation (1999) 3.53
A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci (1996) 3.49
Macrophage complement and lectin-like receptors bind Leishmania in the absence of serum. J Exp Med (1985) 3.44
Arteriovenous malformations of the head and neck: natural history and management. Plast Reconstr Surg (1998) 3.42
Relation of vascular proliferation to tumor growth. Int Rev Exp Pathol (1976) 3.21
The human mannose-binding protein functions as an opsonin. J Exp Med (1989) 3.15
Proteus syndrome: diagnostic criteria, differential diagnosis, and patient evaluation. Am J Med Genet (1999) 3.02
Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg (1966) 3.00
Sclerotherapy of craniofacial venous malformations: complications and results. Plast Reconstr Surg (1999) 2.99
Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest (1994) 2.97
Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol (1996) 2.95
Surface properties of bacillus Calmette-Guérin-activated mouse macrophages. Reduced expression of mannose-specific endocytosis, Fc receptors, and antigen F4/80 accompanies induction of Ia. J Exp Med (1981) 2.89
Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci U S A (1997) 2.88
Self-regulation of growth in three dimensions. J Exp Med (1973) 2.87
How does extracellular matrix control capillary morphogenesis? Cell (1989) 2.84
Polymers for the sustained release of proteins and other macromolecules. Nature (1976) 2.81
Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci U S A (2001) 2.81
A mutation in the homeodomain of the human MSX2 gene in a family affected with autosomal dominant craniosynostosis. Cell (1993) 2.80
Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest (1993) 2.71
How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture. Cancer Res (1986) 2.69
Hemangiomas and vascular malformations of infancy and childhood. Pediatr Clin North Am (1993) 2.69
Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res (1999) 2.58
Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem Biophys Res Commun (1993) 2.56
Local opsonization by secreted macrophage complement components. Role of receptors for complement in uptake of zymosan. J Exp Med (1984) 2.53
Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell (1991) 2.52
Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst (1972) 2.52
Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst (1994) 2.50
Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry (1989) 2.49
Horizontal transfer of DNA by the uptake of apoptotic bodies. Blood (1999) 2.49
Vascular tumors and vascular malformations (new issues). Adv Dermatol (1997) 2.48
Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science (1983) 2.47
A simple procedure for the long-term cultivation of chicken embryos. Dev Biol (1974) 2.46
Tumor angiogenesis. Adv Cancer Res (1974) 2.38
The mannose receptor is a pattern recognition receptor involved in host defense. Curr Opin Immunol (1998) 2.31
Croquemort, a novel Drosophila hemocyte/macrophage receptor that recognizes apoptotic cells. Immunity (1996) 2.30
Protamine is an inhibitor of angiogenesis. Nature (1982) 2.30
Requirement for croquemort in phagocytosis of apoptotic cells in Drosophila. Science (1999) 2.29
Mast cell heparin stimulates migration of capillary endothelial cells in vitro. J Exp Med (1980) 2.27
A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome. Am J Hum Genet (1997) 2.22
Congenital vascular lesions: clinical application of a new classification. J Pediatr Surg (1983) 2.20
Clonality and altered behavior of endothelial cells from hemangiomas. J Clin Invest (2001) 2.20
Vasculogenesis, angiogenesis, and growth factors: ephrins enter the fray at the border. Cell (1998) 2.17
Preservation of vascular integrity in organs perfused in vitro with a platelet-rich medium. Nature (1969) 2.16
Fine structure of vascular endothelium in culture. J Ultrastruct Res (1975) 2.15
Nonsyndromic cleft lip with or without cleft palate: evidence of linkage to BCL3 in 17 multigenerational families. Am J Hum Genet (1995) 2.12
Betacellulin: a mitogen from pancreatic beta cell tumors. Science (1993) 2.10
Heterogeneity of angiogenic activity in a human liposarcoma: a proposed mechanism for "no take" of human tumors in mice. J Natl Cancer Inst (2001) 2.10
Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci U S A (1996) 2.07
Involvement of platelets in tumour angiogenesis? Lancet (1998) 2.03
Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol (1997) 1.98
Pyogenic granuloma (lobular capillary hemangioma): a clinicopathologic study of 178 cases. Pediatr Dermatol (1991) 1.96
Tumor angiogenesis: iris neovascularization at a distance from experimental intraocular tumors. J Natl Cancer Inst (1973) 1.95
Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy. J Pediatr (1998) 1.95
Isolation and characterization of endothelial progenitor cells from mouse embryos. Development (1998) 1.94
Endothelial growth factors and extracellular matrix regulate DNA synthesis through modulation of cell and nuclear expansion. In Vitro Cell Dev Biol (1987) 1.93
Application of the biological principle of induced osteogenesis for craniofacial defects. Lancet (1981) 1.92